ReviewBiochemical pharmacology2020
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.
Review in Biochemical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- The role of the classical renin-angiotensin system and angiotensin-converting enzyme 2/Ang(1-7)/Mas axis in pulmonary fibrosis.Frontiers in medicine · 2025Review
- A comprehensive review of the literature on CD10: its function, clinical application, and prospects.Frontiers in pharmacology · 2024Review
- Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.Biochemical pharmacology · 2023Review
- New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Review
- Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation.Peptides · 2022Review
- Effectiveness of Systemic Corticosteroids Therapy for Nonsevere Patients With COVID-19: A Multicenter, Retrospective, Longitudinal Cohort Study.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022Article
- Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19.PLoS genetics · 2022Article
- The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment.Pharmacology research & perspectives · 2022Review
- Therapeutic Approaches in COVID-19 Patients: The Role of the Renin-Angiotensin System.Canadian respiratory journal · 2022Review
- Bioinformatics insights into the genes and pathways on severe COVID-19 pathology in patients with comorbidities.Frontiers in physiology · 2022Article
- COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy.Health science reports · 2021Review
- Vasoactive Peptides: Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets.Archives of medical research · 2021Review
- Angiotensin receptor blocker neprilysin inhibitors.World journal of cardiology · 2021Review
- Cardiovascular Disease Complicating COVID-19 in the Elderly.Medicina (Kaunas, Lithuania) · 2021Review
- Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?Physiological reports · 2021Review
- Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq.Biochemical pharmacology · 2021Review
- A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era.Frontiers in physiology · 2021Review
- Flow cytometric evaluation of the neutrophil compartment in COVID-19 at hospital presentation: A normal response to an abnormal situation.Journal of leukocyte biology · 2021Article
- New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.European journal of pharmacology · 2020Review
- Neprilysin expression and functions in development, ageing and disease.Mechanisms of ageing and development · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is an ongoing viral pandemic disease that is caused by SARS-CoV2, inducing severe pneumonia in humans. However, several classes of repurposed drugs have been recommended, no specific vaccines or effective therapeutic interventions for COVID-19 are developed till now. Viral dependence on ACE-2, as entry receptors, drove the researchers into RAS impact on COVID-19 pathogenesis. Several evidences have pointed at Neprilysin (NEP) as one of pulmonary RAS components. Considering the protective effect of NEP against pulmonary inflammatory reactions and fibrosis, it is suggested to direct the future efforts towards its potential role in COVID-19 pathophysiology. Thus, the review aimed to shed light on the potential beneficial effects of NEP pathways as a novel target for COVID-19 therapy by summarizing its possible molecular mechanisms. Additional experimental and clinical studies explaining more the relationships between NEP and COVID-19 will greatly benefit in designing the future treatment approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.